01696 SISRAM MED
- 3.630
- -0.010-0.27%
SISRAM MED News
Many star products shine on stage, sisram med has appeared at the Import Expo for seven consecutive years.
On November 11, 2024, Hong Kong /PRNewswire/ -- The 7th China International Import Expo was held grandly in Shanghai from November 5th to 10th. Taking this opportunity, Sisram Medical Technology Co., Ltd. (referred to as 'the Company' or 'Sisram Medical'; English 'Sisram Medical'; stock code: 1696.HK) as a global beauty and health group, continued to showcase its flagship products at the exhibition this year. The company's booth is located in the medical instruments and healthcare area 7.1B03, marking the company's seventh consecutive participation in the Import Expo. Over the years, Sisram Med
Sisram Medical Launches Aesthetic Treatment Platform Alma Harmony's Latest Edition
Sisram Med (01696.HK) announced the launch of the new version of the beauty platform Alma Harmony.
Grandblue 5 November | Sisram Med (01696.HK) announced the launch of its award-winning beauty platform Alma Harmony's new version ('New Alma Harmony'). The new Alma Harmony features a modern design and has been greatly upgraded to provide customers with more treatment options and a simple asia vets user experience. Its innovative personalized patient function integrates five of the most popular technologies and enhanced energy, providing a comprehensive treatment solution. The design focus of the new Alma Harmony is to improve efficiency, simplicity, and ease of use.
sisram med (01696.HK) launches a new version of beauty platform
Sisram Med (01696.HK) announced the launch of a new version of the beauty platform Alma Harmony. The group stated that the new version has undergone a major upgrade, providing customers with more treatment options and a simple Asia vets user experience.
Shenzhen is planning to relax market access for the medical beauty industry, encouraging social capital to enter the medical beauty sector.
Shenzhen has released the "Longhua District's Measures to Support the High-quality Development of the High-end Medical Beauty Industry (Draft for Soliciting Opinions)", mentioning the appropriate relaxation of market access for the medical beauty industry in Longhua District, encouraging social capital to enter the medical beauty industry. Establish a green channel for the approval of the medical beauty industry, simplify procedures such as enterprise registration and medical institution approval, and provide one-stop services for enterprises including industrial and commercial registration and administrative approval. At the same time, actively introduce leading medical beauty listed companies, service-oriented reputable medical beauty institutions, research and development medical beauty companies with mature products on the market, and medical beauty internet channel enterprises to land in Longhua, in accordance with relevant regulations.
Hong Kong stock concept tracking | Medical devices trade-in program attracts institutional attention, clear trend of market recovery.
"Trade-in" is accelerating in the field of medical devices, and various provinces are intensively issuing "feasibility announcements", "project approval announcements" and "tender procurement notices", injecting a dose of "cardiotonic" into the market.
Sisram Medical Names CFO
Sisram Med (01696) appoints Li Jiahong as Chief Financial Officer.
Sisram Med (01696) announced the appointment of Li Jiahong as the company's Chief Financial Officer, effective from October 2024...
Sisram Med (01696.HK): Medical aesthetics business steady with growth, continued efforts in Asia-Pacific and European markets.
Event: On September 19, 2024, the company released the 2024 interim report: In 2024H1, the company achieved revenue of 1.209 billion yuan, a decrease of 1.4% year-on-year; achieved a net income of 0.078 billion yuan, a decrease of 4%.
There is no limit on price fluctuation, new stocks are being speculated! The pioneer of ultrasound submits an application for registration on the gem.
Cumulative dividends exceed 0.3 billion over 4 years.
Sisram Medical Establishes Direct Office in Thailand, Thai Regulator Approves Injection
Sisram Med (01696.HK) announced the establishment of a new direct sales business channel in Thailand.
Grace 9月30日丨Sisram Med (01696.HK) announced the establishment of a new direct sales business channel in Thailand. As the exclusive agent for the injectable filler product Profhilo, which has been approved by the Thai Food and Drug Administration, this direct sales channel will start with injectable filler business and look forward to registering more products in the future to optimize customer experience and choices. The company has been actively seeking to expand direct sales business in suitable strategic markets, enhance interaction with customers, strengthen stickiness with customers and consumers, and increase brand awareness. Thailand is a constantly growing and vibrant market in the global beauty field, as well as an important emerging market in Southeast Asia.
SISRAM MED: INTERIM REPORT 2024
Express News | Citic Sec: Short-term view of the medical beauty industry focuses on track-exclusive products and item development, while the long-term perspective emphasizes platform strength.
Sisram Medical (1696.HK): A leading energy-based medical aesthetic company, building a large medical aesthetic ecosystem.
Global medical beauty industry: expanding scale, high prosperity, non-surgical scale growth rate higher than surgical medical beauty industry. Upstream are raw material and medical device manufacturers, with high barriers to entry and gross margin reaching 80%-95%. Midstream are dealers and medical beauty institutions.
Sirsram Medical Announces NMPA Approval for DAXXIFY
Sisram Med: The world's first patented long-acting peptide type A botulinum toxin, Daxibotin, has officially obtained market approval in China.
Hong Kong, September 9, 2024 /PRNewswire/ -- Sisram Med Limited (referred to as the "Company" or "Sisram Med") (stock code: 1696.HK), together with its subsidiaries (referred to as the "Group"), announced today that the company's revolutionary long-acting type A botulinum toxin product, branded as Daxify (英文商標為DAXXIFY), (project code RT002), has officially received approval from the China National Medical Products Administration for its registration application. This product is used for temporary improvement in adults.
Sisram Med (01696.HK): Injection type A botulinum toxin product Daxifei approved in China.
On September 9, Sisram Med (01696.HK) announced that it has been reauthorized by Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (hereinafter referred to as "Fosun Pharmaceutical Industry") to market the injection product Type A Botulinum Toxin (DaxibotulinumtoxinA-lanm, trademarked as DAXXIFY in English and DaxibotulinumtoxinA-lanm in China). This product is used for temporary improvement of moderate to severe glabellar lines caused by the activity of the corrugator and/or procerus muscles in adults. The pharmaceutical registration application for this drug has recently been approved by the National Medical Products Administration.
Sisram Med (01696.HK) has obtained approval from the National Medical Products Administration for the registration of wrinkle injection drugs.
Sisram Med (01696.HK) announced that it has received approval from the National Medical Products Administration for the registration application of its product, injection type A botulinum toxin (known as DaxiPhi in mainland China), used for the temporary improvement of moderate to severe glabellar lines caused by the activity of the corrugator and procerus muscles in adults. It is reported that a wholly-owned subsidiary of Sisram Med obtained the rights to use, import, sell, and commercialize the product for cosmetic indications in mainland China, Hong Kong, Macau, and the original authorized party is from the United States.
sisram med (01696.HK) granted a total of 1.32 million restricted share units.
On September 4, 2024, Sisram Medical Technology (01696.HK) announced that on September 4, 2021, the company issued a total of 1.32 million restricted stock units to a total of 59 participants under the 2021 Restricted Share Unit Plan. The purpose of this issuance is to effectively attract and retain core talents who have a significant impact and contribution to the company's business growth, stimulate the entrepreneurial passion of core employees, and help the company's healthy and long-term development, which also aligns with the overall interests of the company and shareholders. The recipients of this issuance are all new assignees, meaning they did not receive restricted stock units under the 2021 Restricted Share Unit Plan.
Analysis
Price Target
No Data
No Data